Effects of lacidophilin in a mouse model of low-grade colitis and nonalcoholic fatty liver disease

Abstract

Lacidophilin, which is a bacteriocin produced by food-grade lactic acid bacteria, modulates the gut microbiota structure to enhance gut health. This study investigated the effects and mechanism of lacidophilin in a mouse model of low-grade colitis and NAFLD. After 126 days of feeding and medication intervention, high-dose lacidophilin (1.2 g per kg body weight) mitigated NAFLD-associated changes in biochemical parameters and prevented hyperlipidemia and hepatic lipid accumulation. Additionally, lacidophilin exerted a protective effect by reducing damage to the intestinal barrier (ZO-1/Mucin 2), increasing the relative abundance of Lachnospiraceae and Prevotellaceae, decreasing the relative abundance of Erysipelotrichaceae in low-grade colitis and NAFLD mice. In addition, fecal metabolomics studies showed that lacidophilin could regulate both amino acid and lipid metabolism to protect against NAFLD. Flow cytometry analysis of blood samples showed that lacidophilin could regulate the balance of Th1/Th2 and Th17/Treg. Transcriptomic analysis of the liver suggests that treatment with lacidophilin helped maintain immune homeostasis and facilitate lipid metabolism. In short, lacidophilin extracts alleviated lipid accumulation and inflammation in NAFLD mice.